Time-Cap Labs Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
Time-Cap Labs, Inc. is recalling Metformin Hydrochloride Extended-Release Tablets 500 mg because the FDA detected the impurity N-Nitrosodimethylamine (NDMA) above acceptable intake levels.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), particularly when involving significant chemical impurities like NDMA.
Plain-English summary
Time-Cap Labs, Inc. is recalling Metformin Hydrochloride Extended-Release Tablets USP 500 mg. The recall involves 90-count, 100-count, 500-count, and 1000-count bottles manufactured by Marksans Pharma Limited. The products are distributed nationwide.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the FDA detected the impurity N-Nitrosodimethylamine (NDMA) above the acceptable intake level. The agency has classified this recall as Class II.
Consumers who have these specific bottles should stop using the medication and contact their healthcare provider for guidance. The affected products are identified by specific NDC codes and lot codes listed in the official recall notice.
The recalled product
- Product
- METFORMIN HYDROCHLORIDE EXTENDED RELEASE (METFORMIN HYDROCHLORIDE)
- Brand
- METFORMIN HYDROCHLORIDE EXTENDED RELEASE
- Manufacturer
- Marksans Pharma Limited
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- a) 90 count: E072F
- E074F
- E076F Oct-20
- D096F
- H029F
- H031F
- XP8276
- XP8289 Nov-20
- L007F
- J022F
- H039F
- Dec-20
- J092F Jan-21
- L055F Jun-21
- K079F Jul-21
- A002G
- A003G
- A007G Aug-21
- A49001 Nov-21
- A40001
UPCs (3)
- 0349483624014
- 0349483623109
- 0349483623017
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Marksans Pharma Limited under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · METFORMIN HYDROCHLORIDE EXTENDED RELEASE
- SevereDirect Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SeverePD-Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SeverePD-Rx Recalls Metformin Hydrochloride Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-11-11
- SevereMetformin Hydrochloride Extended Release Tablets Recalled for NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereTime-Cap Labs Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA
FDA (Drugs) · 2020-07-01
Same hazard · ndma impurity
See all →- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets
FDA (Drugs) · 2021-05-26
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-02-10
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-01-20
- SevereDenton Pharma Recalls Metformin Hydrochloride Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11